Trastuzumab cardiotoxicity: Speculations regarding pathophysiology and targets for further study

Jay W. Schneider, Alice Y. Chang, Alistair Garratt

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Trastuzumab, a monoclonal antibody that is selective for cells that overexpress the erbB2 receptor protein tyrosine kinase, is a promising targeted therapy for the treatment of breast cancer. Surprisingly, toxic cardiovascular side effects were discovered in late-phase clinical trials, and these effects were most prominent when trastuzumab was combined with anthracycline chemotherapy. We review recent data focusing on how erbB2 monoclonal antibodies could exert a cardiotoxic effect through unique cardiomyocyte cell surface and intracellular structural features, and how an individual's cardiac susceptibility to erbB2 monoclonal antibodies may be dictated by the ability of erbB2 monoclonal antibodies to bind cardiomyocytes. In addition, we discuss ways that anthracyclines may also affect erbB2/erbB4/neuregulin receptor signaling, explaining the apparent synergistic effect. Further investigation of the role of normal and aberrant erbB2 signaling in the development of cardiac dysfunction could lead to an improved understanding of the pathophysiology of cardiac dysfunction and may lead to novel therapies for the treatment of heart failure, regardless of etiology. Understanding the nature and specificity of trastuzumab's cardiotoxic effects is important in better defining clinical criteria for inclusion and exclusion of patients who can safely receive trastuzumab for the treatment of breast cancer, or possibly other malignancies.

Original languageEnglish (US)
Pages (from-to)22-28
Number of pages7
JournalSeminars in Oncology
Volume29
Issue number3 SUPPL. 11
StatePublished - 2002

Fingerprint

Monoclonal Antibodies
Anthracyclines
Cardiac Myocytes
Neuregulins
Breast Neoplasms
Poisons
Receptor Protein-Tyrosine Kinases
Therapeutics
Treatment Failure
Heart Failure
Clinical Trials
Drug Therapy
Cardiotoxicity
Trastuzumab
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Trastuzumab cardiotoxicity : Speculations regarding pathophysiology and targets for further study. / Schneider, Jay W.; Chang, Alice Y.; Garratt, Alistair.

In: Seminars in Oncology, Vol. 29, No. 3 SUPPL. 11, 2002, p. 22-28.

Research output: Contribution to journalArticle

Schneider, Jay W. ; Chang, Alice Y. ; Garratt, Alistair. / Trastuzumab cardiotoxicity : Speculations regarding pathophysiology and targets for further study. In: Seminars in Oncology. 2002 ; Vol. 29, No. 3 SUPPL. 11. pp. 22-28.
@article{13e078e859e246c1ba74cad4e318778e,
title = "Trastuzumab cardiotoxicity: Speculations regarding pathophysiology and targets for further study",
abstract = "Trastuzumab, a monoclonal antibody that is selective for cells that overexpress the erbB2 receptor protein tyrosine kinase, is a promising targeted therapy for the treatment of breast cancer. Surprisingly, toxic cardiovascular side effects were discovered in late-phase clinical trials, and these effects were most prominent when trastuzumab was combined with anthracycline chemotherapy. We review recent data focusing on how erbB2 monoclonal antibodies could exert a cardiotoxic effect through unique cardiomyocyte cell surface and intracellular structural features, and how an individual's cardiac susceptibility to erbB2 monoclonal antibodies may be dictated by the ability of erbB2 monoclonal antibodies to bind cardiomyocytes. In addition, we discuss ways that anthracyclines may also affect erbB2/erbB4/neuregulin receptor signaling, explaining the apparent synergistic effect. Further investigation of the role of normal and aberrant erbB2 signaling in the development of cardiac dysfunction could lead to an improved understanding of the pathophysiology of cardiac dysfunction and may lead to novel therapies for the treatment of heart failure, regardless of etiology. Understanding the nature and specificity of trastuzumab's cardiotoxic effects is important in better defining clinical criteria for inclusion and exclusion of patients who can safely receive trastuzumab for the treatment of breast cancer, or possibly other malignancies.",
author = "Schneider, {Jay W.} and Chang, {Alice Y.} and Alistair Garratt",
year = "2002",
language = "English (US)",
volume = "29",
pages = "22--28",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "3 SUPPL. 11",

}

TY - JOUR

T1 - Trastuzumab cardiotoxicity

T2 - Speculations regarding pathophysiology and targets for further study

AU - Schneider, Jay W.

AU - Chang, Alice Y.

AU - Garratt, Alistair

PY - 2002

Y1 - 2002

N2 - Trastuzumab, a monoclonal antibody that is selective for cells that overexpress the erbB2 receptor protein tyrosine kinase, is a promising targeted therapy for the treatment of breast cancer. Surprisingly, toxic cardiovascular side effects were discovered in late-phase clinical trials, and these effects were most prominent when trastuzumab was combined with anthracycline chemotherapy. We review recent data focusing on how erbB2 monoclonal antibodies could exert a cardiotoxic effect through unique cardiomyocyte cell surface and intracellular structural features, and how an individual's cardiac susceptibility to erbB2 monoclonal antibodies may be dictated by the ability of erbB2 monoclonal antibodies to bind cardiomyocytes. In addition, we discuss ways that anthracyclines may also affect erbB2/erbB4/neuregulin receptor signaling, explaining the apparent synergistic effect. Further investigation of the role of normal and aberrant erbB2 signaling in the development of cardiac dysfunction could lead to an improved understanding of the pathophysiology of cardiac dysfunction and may lead to novel therapies for the treatment of heart failure, regardless of etiology. Understanding the nature and specificity of trastuzumab's cardiotoxic effects is important in better defining clinical criteria for inclusion and exclusion of patients who can safely receive trastuzumab for the treatment of breast cancer, or possibly other malignancies.

AB - Trastuzumab, a monoclonal antibody that is selective for cells that overexpress the erbB2 receptor protein tyrosine kinase, is a promising targeted therapy for the treatment of breast cancer. Surprisingly, toxic cardiovascular side effects were discovered in late-phase clinical trials, and these effects were most prominent when trastuzumab was combined with anthracycline chemotherapy. We review recent data focusing on how erbB2 monoclonal antibodies could exert a cardiotoxic effect through unique cardiomyocyte cell surface and intracellular structural features, and how an individual's cardiac susceptibility to erbB2 monoclonal antibodies may be dictated by the ability of erbB2 monoclonal antibodies to bind cardiomyocytes. In addition, we discuss ways that anthracyclines may also affect erbB2/erbB4/neuregulin receptor signaling, explaining the apparent synergistic effect. Further investigation of the role of normal and aberrant erbB2 signaling in the development of cardiac dysfunction could lead to an improved understanding of the pathophysiology of cardiac dysfunction and may lead to novel therapies for the treatment of heart failure, regardless of etiology. Understanding the nature and specificity of trastuzumab's cardiotoxic effects is important in better defining clinical criteria for inclusion and exclusion of patients who can safely receive trastuzumab for the treatment of breast cancer, or possibly other malignancies.

UR - http://www.scopus.com/inward/record.url?scp=0036316232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036316232&partnerID=8YFLogxK

M3 - Article

C2 - 12138394

AN - SCOPUS:0036316232

VL - 29

SP - 22

EP - 28

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 3 SUPPL. 11

ER -